A recent report indicated that a novel EGFR-targeting RNase A-cetuximab antibody-drug conjugate (RN-PEG-Cet) potentially induces DNA fragmentation and ROS-mediated cellular death in KRAS-mutant CRC (Jafary et al., 2025). This evidence concerns the gene KRAS and colorectal carcinoma.